Melanoma, an aggressive form of skin cancer, remains one of the most formidable due to its ability to spread rapidly and its resistance to conventional treatments such as chemotherapy. Although it accounts for only 5% of skin cancers, it is responsible for the majority of deaths related to these tumors. Its incidence has increased significantly in recent decades, particularly among people over 60 in Europe, North America, and Oceania.<\/p>\n
Immunotherapy has marked a turning point in the management of melanoma by harnessing the unique features of the immune system to fight the disease. Melanoma cancer cells often carry numerous mutations caused by ultraviolet radiation damage. These mutations create abnormal proteins that can be recognized by the immune system, making this cancer particularly vulnerable to treatments that stimulate the body’s natural defenses.<\/p>\n
Immunotherapies work by blocking the mechanisms that tumor cells use to evade immune surveillance. For example, drugs targeting the PD-1, CTLA-4, or LAG-3 proteins can reactivate T lymphocytes, immune cells capable of destroying cancer cells. These treatments, known as immune checkpoint inhibitors, have significantly improved the survival of patients with advanced melanoma. Studies show that some patients treated with these therapies see their life expectancy exceed several years, whereas it was once limited to just a few months.<\/p>\n
However, not all patients respond in the same way. Some develop resistance over time, while others do not respond at all. To overcome these challenges, researchers are exploring new drug combinations and innovative approaches, such as cellular therapies or personalized vaccines. These advances aim to enhance the effectiveness of immunotherapies and reduce side effects, which can sometimes be severe.<\/p>\n
The use of these treatments in combination with surgery, radiotherapy, or chemotherapy is also under investigation. The goal is to optimize outcomes and provide tailored solutions for each patient, based on the characteristics of their tumor and their overall health. Thanks to these advances, metastatic melanoma, once considered a death sentence, is becoming a disease that can be better controlled, and in some cases, even cured.<\/p>\n
DOI:<\/strong> https:\/\/doi.org\/10.1007\/s11912-026-01750-1<\/a><\/p>\n Title:<\/strong> Immune Checkpoint Inhibitors in Malignant Melanoma: Anti-PD-1, Anti-CTLA-4 and Anti-LAG-3 Therapies<\/p>\n Journal:<\/strong> Current Oncology Reports<\/p>\n Publisher:<\/strong> Springer Science and Business Media LLC<\/p>\n Authors:<\/strong> Andrea M. Allen-Tejerina; Periklis Giannakis; Thomas Ho Lai Yau; Christopher R. T. Hillyar; Kathrine S. Rallis<\/p>\n","protected":false},"excerpt":{"rendered":" Are Immunotherapies Transforming the Treatment of Metastatic Melanoma? Melanoma, an aggressive form of skin cancer, remains one of the most formidable due to its ability to spread rapidly and its resistance to conventional treatments such as chemotherapy. Although it accounts for only 5% of skin cancers, it is responsible for the majority of deaths related… Continue reading Are Immunotherapies Transforming the Treatment of Metastatic Melanoma?<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-18","post","type-post","status-publish","format-standard","hentry","category-health","entry"],"_links":{"self":[{"href":"https:\/\/themedicaltribune.com\/en\/wp-json\/wp\/v2\/posts\/18","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/themedicaltribune.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/themedicaltribune.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/themedicaltribune.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/themedicaltribune.com\/en\/wp-json\/wp\/v2\/comments?post=18"}],"version-history":[{"count":1,"href":"https:\/\/themedicaltribune.com\/en\/wp-json\/wp\/v2\/posts\/18\/revisions"}],"predecessor-version":[{"id":19,"href":"https:\/\/themedicaltribune.com\/en\/wp-json\/wp\/v2\/posts\/18\/revisions\/19"}],"wp:attachment":[{"href":"https:\/\/themedicaltribune.com\/en\/wp-json\/wp\/v2\/media?parent=18"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/themedicaltribune.com\/en\/wp-json\/wp\/v2\/categories?post=18"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/themedicaltribune.com\/en\/wp-json\/wp\/v2\/tags?post=18"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}